Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
52.21M | 37.20M | 2.06M | 2.72M | 3.56M | 1.65M | Gross Profit |
45.72M | 31.02M | 1.43M | 2.03M | 2.88M | 1.01M | EBIT |
-1.49M | -12.41M | -38.18M | -33.85M | -24.53M | -21.30M | EBITDA |
-3.53M | -12.18M | -46.11M | -33.69M | -24.00M | -23.79M | Net Income Common Stockholders |
-14.21M | -26.39M | -47.68M | -39.16M | -26.76M | -24.48M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
10.00M | 53.23M | 32.45M | 7.67M | 22.80M | 28.57M | Total Assets |
14.21M | 76.59M | 38.61M | 17.86M | 33.12M | 34.63M | Total Debt |
2.86M | 1.04M | 10.19M | 15.87M | 16.25M | 2.94M | Net Debt |
-7.14M | -31.37M | -2.46M | 8.20M | -6.55M | -25.63M | Total Liabilities |
20.57M | 7.84M | 22.84M | 23.72M | 21.17M | 12.56M | Stockholders Equity |
-6.36M | 68.75M | 15.78M | -5.86M | 11.95M | 22.08M |
Cash Flow | Free Cash Flow | ||||
-7.58M | -19.24M | -31.31M | -25.16M | -22.75M | -23.65M | Operating Cash Flow |
-6.89M | -18.68M | -31.25M | -24.95M | -22.60M | -22.87M | Investing Cash Flow |
-30.79M | -981.00K | -19.71M | -209.00K | -143.00K | -782.00K | Financing Cash Flow |
38.64M | 39.41M | 51.78M | 10.14M | 20.82M | 42.35M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
61 Neutral | $570.45M | ― | -29.95% | ― | 1068.87% | 81.29% | |
55 Neutral | $622.77M | ― | -49.97% | ― | -14.16% | 25.80% | |
54 Neutral | $5.31B | 3.26 | -45.10% | 2.79% | 16.76% | 0.02% | |
52 Neutral | $420.40M | ― | -16.96% | ― | -14.96% | -245.49% | |
46 Neutral | $610.86M | ― | 0.71% | ― | 91657.69% | 97.21% | |
43 Neutral | $662.54M | ― | -48.45% | ― | ― | 7.15% | |
34 Underperform | $453.26M | ― | -45.82% | ― | ― | 10.38% |
On May 22, 2025, Delcath Systems announced its full-year 2025 financial guidance, projecting total revenue between $94 to $98 million, marking a significant increase of over 150% from 2024. The company also plans to enter into a National Medicaid Drug Rebate Agreement with the Centers for Medicare & Medicaid Services, expected to take effect in the third quarter of 2025, which aims to expand patient access and accelerate the adoption of its HEPZATO treatment in the U.S.
The most recent analyst rating on (DCTH) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Delcath Systems stock, see the DCTH Stock Forecast page.
At the annual meeting on May 15, 2025, Delcath Systems‘ stockholders approved amendments to increase the number of shares available under the company’s 2020 Omnibus Equity Incentive Plan and 2021 Employee Stock Purchase Plan. Additionally, stockholders elected Class I directors, ratified the selection of the company’s independent public accounting firm, and approved a non-binding advisory vote on executive compensation, reflecting shareholder support for the company’s strategic initiatives.
The most recent analyst rating on (DCTH) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Delcath Systems stock, see the DCTH Stock Forecast page.